


Eribaxaban

Chemical Properties

CAS No. :	536748-46-6
Formula:	C ₂₄ H ₂₂ ClFN ₄ O ₄
Molecular Weight:	484.91
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Eribaxaban (PD348292) is an orally available factor Xa inhibitor for the prevention and treatment of venous thromboembolism.
Targets(IC50)	Factor Xa

Solubility Information

Solubility	DMSO: 75 mg/mL (154.67 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 7.5 mg/mL (15.47 mM), Solution. 10% DMSO+90% Saline: < 7.5 mg/mL (15.47 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0622 mL	10.3112 mL	20.6224 mL
5 mM	0.4124 mL	2.0622 mL	4.1245 mL
10 mM	0.2062 mL	1.0311 mL	2.0622 mL
50 mM	0.0412 mL	0.2062 mL	0.4124 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Bondarenko M, et al. Efficacy and toxicity of factor Xa inhibitors. J Pharm Pharm Sci. 2013;16(1):74-88.

Lippi G, et al. Current and Emerging Direct Oral Anticoagulants: State-of-the-Art. Semin Thromb Hemost. 2019 Jul; 45(5):490-501.

Remko M, et al. Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors. Molecules. 2016 Feb 4;21(2):185.

Wang Z, et al. Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis. Cell Physiol Biochem. 2017;42(5):1999-2020.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481